Skip to main content
Fig. 9 | Journal of Neuroinflammation

Fig. 9

From: Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease

Fig. 9

TG11-77.HCl is highly selective to EP2 receptor, and achieves adequate plasma and brain concentrations upon oral dosing. A Plasma concentrations of TG11-77.HCl in 8–12-week-old female C57BL/6 mice (n = 4) by oral dosing from day 1 to 6 (with projected dose of 100 mg/kg/day). Schild KB is indicated by dotted line. B On day 7, the concentration in the brain was measured with a brain-to-plasma ratio 0.46–4 depending on the timing of the analysis. Dotted line in both A and B represents the potency of TG11-77.HCl (Schild KB = 9.7 nM). C Plasma concentration with increasing timepoints (0.5, 2 and 4 h) after single dose IP injection of TG11-77.HCl (10 mg/kg) in male and female C57BL/6 mice (n = 3). ND: concentrations not detected. Dotted line represents the potency (Schild KB) of TG11-77.HCl = 9.7 nM. D EP2 Selectivity was determined by measuring the potency of TG11-77.HCl for other prostanoid receptors (EP4, DP1 and IP) by a cAMP mediated TR-FRET assay using human EP2 expressed C6-gloma cells as shown before [49]

Back to article page